Deal-Making Insights for the Life Sciences Industry
March 9–10, 2021 Virtual Event
BROUGHT TO YOU BY


Cross-functional perspectives on successfully identifying and executing strategic partnerships, licensing and M&A deals
With so many factors affecting the potential value of a transaction, it is essential for life science organizations to effectively assess the risks associated with a deal, explore innovative models and deal structures for working with strategic partners, collaborate with cross-functional partners to realize business synergies, and develop processes for the efficient and optimal negotiation and closing of a transaction.
The BD&L Summit for Life Sciences will provide attendees with valuable insights and actionable strategies from cross-functional business development teams on successfully managing alliances, licensing agreements, and M&A deals. This event serves as an educational platform for industry experts responsible for R&D, search and evaluation, external innovation, legal/IP, portfolio management, alliance management, business development and licensing, and will feature leadership representation from biotechs, mid-sized and large pharmaceutical, medical device and diagnostics companies.
2021 Featured Speakers

William Coppola
AERIE PHARMACEUTICALS
Intellectual Property Counsel

Michael Flaschen
MERCK
Head of HQ Transactions

Olga Kay
ROCHE MOLECULAR SYSTEMS (Diagnostics)
Senior IP Counsel

Ahmed Mousa
PIERIS PHARMACEUTICALS
SVP Corporate Operations & General Counsel

Michael Myers
ELI LILLY
Sr. Director - Lilly Research Labs, Due Diligence

Jason Okazaki
ASSEMBLY BIOSCIENCES
Chief Legal and Business Officer

Martin Picard
MERCK KGaA
Head of External R&D, Global Research & Development

Cody Powers
ZS ASSOCIATES
Principal

Michael Shih
SANOFI
Head of Global Transactions, Sanofi Partnering

Chris Slavinsky
PHARMACOSMOS THERAPEUTICS, INC.
General Counsel
The Fierce Virtual Experience

Expert Sessions

Networking

Partner Content Hub

Always On
